Pancreas cancer remains one of the deadliest cancers: it is often diagnosed late, progresses rapidly and resists conventional treatments. Despite a lower impact than other tumors, it causes almost as many deaths as new cases each year. In a context where survival rates have been stagnating for decades, research efforts are focused on therapeutic levers so far deemed inaccessible.
In recent years, concrete tracks are emerging: targeting key genetic mutations, the development of tailor -made mesing RNA vaccines, exploration of the role of microbiota, and the use of artificial intelligence to improve detection. Long considered a therapeutic impasse, could this cancer be approached otherwise? What was still unlikely ten years ago is today the subject of high potential clinical trials. The change of course is discreet, but real.
The discreet killer with implacable figures
Pancreas cancer, dominated by pancreatic canal adenocarcinoma, remains today one of the deadliest cancers. In France, it causes nearly 13,000 deaths each year for around 14,000 new cases. The five -year survival rate remains less than 13 %. According to the Inca and the WHO (Globocan 2023), it could become the second cause of cancer death by 2030, behind lung cancer.
The late diagnosis Econsituits a key factor. Indeed, its clinical stealth largely explains this lethality. Professor Alain Toledano, cancerologist at the Hartmann Radiotherapy Center, President of the Rafaël Institute and Director of the Integrative Health Chair at the National Conservatory of Arts and Crafts, recalls: “The pancreas is a deep organ. The tumors evolve there silently. They often only cause symptoms when they are already advanced or metastatic ”.
The disease increases quickly: more than 50 % of patients are diagnosed at a metastatic stage. Their median survival is within a year despite chemotherapy.
To this is added a particularly resistant biology. Tumor microenvironnement forms a physical and immunological barrier: dense fibrous tissue, hypoxia, low infiltration of immune cells.
“This cancer develops strong resistance to treatments. Chemotherapy has a limited effect, and immunotherapy, very promising elsewhere, is almost never effective here ”, Specifies Professor Toledano, contacted by email. He adds that even when the tumor is operable, which only concerns 15 to 20 % of patients, the risks of recurrence remain very high. In question the early dissemination of cancer cells in the body. Finally, no organized screening exists to date. Only high -risk patients (BRCA mutation, family history) benefit from targeted surveillance.
Kras: the fault finally explored
Faced with this therapeutic impasse, research focused on a genetic target common to the vast majority of cases: the Kras mutation. Indeed, the Kras gene is transferred to more than 90 % of pancreas cancers. In fact, it activates molecular waterfalls promoting tumor proliferation, immune exhaust and treatment resistance. Professor Alain Toledano explains: “The KRAS mutation was historically difficult to target with drugs, which has earned it to be described as” untouchable target “”.
The emergence of inhibitors like Sotorasib or Adagrasib, effective on the Kras G12C mutation, has opened up new perspectives. “” They work by blocking the activity of this mutated form of kras. This prevents the growth and proliferation of cancer cells ». But this mutation only concerns 1 to 2 % of pancreatic patients. The current challenge? Target the forms G12D and G12V, much more frequent.
Recent work carried out by David S. Hong (MD Anderson Cancer Center) and Ryan B. Corcoran (Massachusetts General Hospital) show that the MRTX1133 molecule, directed against Kras G12D, produced objective responses in preclinical. But it remains in phase I in humans.
Professor Toledano recalls the limits: “Although these advances in kras targeting are significant, current and developing inhibitors need more clinical tests to assess their effectiveness and safety in pancreatic cancer. »»
Message RNA, finally a sustainable immune response?
Messenger RNA technology, which has upset the fight against COVVI-19, is today tested as a treatment for pancreatic cancer. Unlike a preventive vaccine, this therapeutic vaccine is designed from the genetic profile of each tumor. So you can stimulate a targeted immune response.
“Personalized mRNA vaccines represent an innovative and promising approach in cancer treatment, including pancreatic cancer. They are developed according to the specific changes present in the patient tumor ”, explains Professor Alain Toledano. “These vaccines encourage the immune system to recognize cancer cells as threats, which can lead to a more vigorous and lasting response.”
In a phase I clinical trial, published in Nature And coordinated by Dr Vinod Balachandran (Memorial Sloan Kettering, New York), 16 operated patients received a personalized vaccine developed by Biontech and Genentech, associated with chemotherapy and immunotherapy. Result ? Eight patients have developed a strong immune response, with T cells capable of recognizing their tumor. Six of them were still in remission three years later. This result upsets a hitherto dominant hypothesis: that which the pancreas would offer few mutated targets exploitable by a vaccine. Phase II tests are underway. “Universal” approaches, based on frequent mutations like Kras, are currently explored.
Detect invisible: artificial intelligence at the service of diagnosis
As mentioned above, late diagnosis remains one of the main mortality factors in pancreatic cancer. Unlike other cancers – such as breast (mammography) or colon (fecal immunological test, colonoscopy) – there is no validable and generalizable screening test for this disease. The pancreas, located deeply in the abdomen, is not very accessible to routine exams. And the tumor often remains silent up to an advanced stage.
In some cases, the diagnosis may occasionally occur. Namely during an abdominal imaging prescribed for another reason, or in the supervision of pancreatic cysts, considered as potentially pioneers. In high -risk patients – BRCA, CDKN2A or STK11 mutations, or with family history – targeted surveillance is sometimes set up, but without standardized protocol.
Several teams, including those of the Massachusetts General Hospital and the University of Florence (ESMO Open, 2024), develop AI models capable of analyzing MRI, scanners and genetic data to identify early pancreatic anomalies. These systems learn to recognize motifs invisible to human eye. These subtleties could correspond to a pre-cancerous lesion or a high risk of transformation cyst.
Professor Alain Toledano confirms: “AI systems are already under development and some are tested in clinical areas. We can hope to see clinically validated tools in the coming years, but the wide deployment will take time. ”
The AI will not replace clinicians, but it could become a complementary tool, capable of triggering further examinations in asymptomatic patients. In cancer as silent as the pancreas, this technological rupture could transform life expectancy.
A turning point? Yes, but not yet a revolution
After decades of stagnation, pancreatic cancer is gradually opening up to a new therapeutic approach: integrated, targeted, combined. It is no longer a unique molecule that is expected. Indeed, we aim for a reasoned chain of interventions, designed to bypass the tumor resistance and exploit the biological specificities of each patient.
Professor Alain Toledano sums up this perspective. “Treatment of the disease will require a combined approach, potentially including KRAS inhibitors, immunotherapy and other targeted agents.”
This logic is already embodied in several in progress tests. One of the most original was taken in 2025 by the University of Adelaide. This is the first human clinical trial in the world combining chemotherapy and faecal transplantation (FMT) in patients with inoperable pancreatic cancer. By trying to restore the intestinal microbiota before chemotherapy, the team hopes to improve the immune response and extend survival.
But if the scientific bases are laid, the challenges remain numerous: clinical validation, industrialization, accessibility. Pancreas cancer has not yet become a controllable disease. But the therapeutic framework changes, and with it, the ambition of researchers.
It's not just about winning a few months. It is now a question of completely rethinking the way of diagnosing, treating and anticipating this disease. This is, perhaps, the real turning point.
With an unwavering passion for local news, Christopher leads our editorial team with integrity and dedication. With over 20 years’ experience, he is the backbone of Wouldsayso, ensuring that we stay true to our mission to inform.
